‘Insourcing’ jobs to US could mean tax breaks for drug makers
This article was originally published in Scrip
US drug makers could be among those that stand to gain from new tax incentives President Barack Obama plans to unveil in the coming weeks aimed at rewarding firms that bring jobs back into the US, while those that move jobs overseas will see certain tax advantages eliminated.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.